comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder a prospective, open, randomized, parallel-group trial (the list study)英文论文.pdfVIP

Hindawi Publishing Corporation Advances in Urology Volume 2011, Article ID 854697, 12 pages doi:10.1155/2011/854697 Clinical Study Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) Masayoshi Zaitsu,1 Koji Mikami,1 Noriko Ishida,2 and Takumi Takeuchi1 1 Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan 2 Department of Pharmacy, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan Correspondence should be addressed to Takumi Takeuchi, takeuchit@abelia.ocn.ne.jp Received 22 June 2011; Accepted 19 August 2011 Academic Editor: Hiep T. Nguyen Copyright © 2011 Masayoshi Zaitsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term intervention. Methods. We conducted a 52-week prospective randomized comparative study to evaluate the efficacy and tolerability of two anticholinergics. Results. Forty-one Japanese patients with untreated OAB were randomly assigned to imidafenacin and solifenacin groups. There was no difference in OABSS and KHQ scores between the two groups, but the severity and incidence of adverse events caused by the anticholinergics showed increased differences between the groups with time. The severity of dry